The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
The U.S. Meals and Drug Administration (FDA) has granted breakthrough remedy designation to INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody supposed...
The U.S. Meals and Drug Administration (FDA) has accepted Enhertu (fam-trastuzumab deruxtecan-nxki) together with Perjeta (pertuzumab) for the first-line remedy of adults...
